AFFF firefighting foam lawsuit MDL 2873: how the PFAS personal injury litigation actually works

The AFFF firefighting foam litigation is one of the largest active mass torts in the United States, with MDL 2873 (In re: Aqueous Film-Forming Foams Products Liability Litigation) consolidating more than 15,200 personal injury cases plus thousands of water contamination claims as of April 2026. The case theory alleges that aqueous film-forming foam, used for decades to extinguish liquid fuel fires at military bases, airports, firefighter training facilities, and industrial sites, contains per- and polyfluoroalkyl substances (PFAS) including perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS) that don't degrade naturally and accumulate in the human body. Firefighters, military personnel, airport workers, and residents living near contaminated sites who developed cancer or other serious health conditions allege the manufacturers knew of the cancer risks but continued selling AFFF for decades without adequate warnings.

The litigation is centralized in the U.S. District Court for the District of South Carolina before Judge Richard M. Gergel. The MDL was created on December 7, 2018 by consolidation of approximately 75 lawsuits. As of April 2026 the docket has grown to 15,222 pending personal injury cases, with the case count increasing by approximately 1,000 cases per month through 2025 as plaintiffs' counsel screened and signed up additional clients. The water contamination side of the litigation (cases brought by public water suppliers, municipalities, and states alleging AFFF contamination of drinking water sources) has produced substantial settlements that have reshaped the broader PFAS regulatory and litigation environment.

The personal injury bellwether trials have been delayed multiple times. The first bellwether trial was scheduled for October 6, 2025 focusing on kidney cancer claims but was vacated by Case Management Order No. 35 on August 15, 2025. The court has been working through Daubert challenges and scientific evidence questions through "Science Day" proceedings, including a June 20, 2025 session focused on thyroid and liver cancer causation. The bellwether trial schedule is being reset as the science proceedings continue. When personal injury bellwethers do reach trial, the verdicts will substantially affect settlement valuation across the broader inventory of cases.

This is the science behind the PFAS-cancer theory, the procedural history of the MDL, the settlements that have already occurred on the water contamination side, the eligibility framework for filing-eligible personal injury claims, and the strategic considerations for both pending and prospective plaintiffs.

What is AFFF firefighting foam and why does it matter?

AFFF (aqueous film-forming foam) is a specialized firefighting agent developed in the 1960s that contains PFAS "forever chemicals," including PFOA and PFOS. Used for over 50 years at military bases, airports, and industrial sites, AFFF created persistent environmental contamination at hundreds of locations and is linked to cancer and other serious health conditions in exposed populations.

AFFF (aqueous film-forming foam) is a specialized firefighting foam developed in the 1960s by the U.S. Navy and 3M for use against liquid fuel fires that water alone cannot extinguish. The foam creates a film over the burning liquid that smothers the fire and prevents reignition. AFFF was the standard firefighting agent for military bases, civilian airports, oil refineries, chemical plants, and similar high-risk facilities for more than 50 years.

The foam's effectiveness comes from PFAS compounds, particularly PFOA and PFOS. These compounds are extraordinarily stable carbon-fluorine bonds that don't break down naturally in the environment, leading to their common name "forever chemicals." PFAS compounds:

Resist water and oil, which is why they make effective firefighting foam.

Don't degrade in the environment under normal conditions; PFAS contamination persists for decades or longer.

Bioaccumulate in human and animal tissue. Once absorbed, PFAS compounds remain in the body for years.

Have been linked through scientific research to multiple cancers and other serious health conditions.

The widespread use of AFFF created persistent environmental contamination at hundreds of military bases, airports, and industrial sites. Groundwater contamination from AFFF use has affected drinking water supplies in communities surrounding these sites. The Department of Defense identified over 600 military installations with confirmed or suspected PFAS contamination, and the Environmental Protection Agency has identified thousands of additional contamination sites nationwide.

The Department of Defense required transition away from AFFF as of October 1, 2024, replacing it with fluorine-free firefighting foam alternatives. The transition reflects acknowledgment of the long-term contamination and health risks from continued AFFF use.

What is the scientific evidence linking PFAS exposure to cancer?

Scientific research has established strong links between PFAS exposure and several cancers, with kidney cancer (renal cell carcinoma) and testicular cancer showing the strongest evidence. Growing evidence also supports connections to thyroid cancer, liver cancer, ulcerative colitis, and prostate cancer. Firefighters and military personnel show approximately triple the PFAS blood levels of the general population.

The scientific evidence linking PFAS exposure to cancer and other diseases has strengthened substantially over the past decade. Key findings:

Kidney cancer. The strongest scientific evidence links PFAS exposure to renal cell carcinoma. Multiple peer-reviewed studies have established the connection, including population-level studies of firefighters and military personnel with elevated PFAS exposure.

Testicular cancer. Strong scientific evidence links PFAS exposure to testicular germ cell tumors. A 2023 study by the National Cancer Institute found statistically significant association between PFAS exposure and testicular cancer among U.S. service members.

Thyroid cancer and thyroid disease. Growing evidence links PFAS exposure to thyroid cancer, thyroid nodules, and various thyroid function abnormalities. The Court held a dedicated Science Day on June 20, 2025 focused on thyroid and liver cancer causation questions.

Liver cancer and liver disease. Evidence is developing for liver cancer and various liver function abnormalities including elevated liver enzymes and fatty liver disease.

Ulcerative colitis. Strong scientific evidence links PFAS exposure to ulcerative colitis and other inflammatory bowel diseases.

Prostate cancer. Some studies suggest association between PFAS exposure and prostate cancer, though the evidence is less definitive than for kidney and testicular cancer.

Other conditions. High cholesterol, pregnancy-induced hypertension, pre-eclampsia, reduced immune response to vaccinations, and various other conditions have shown statistical association with PFAS exposure.

The mechanism of PFAS toxicity is multi-faceted. PFAS compounds disrupt cellular processes through multiple pathways, accumulate in liver and kidney tissues, and persist in the body for years (PFOS has a half-life of approximately 5.4 years in humans). The bioaccumulation means even relatively low chronic exposure can result in significant body burden over time.

Studies have shown that firefighters have approximately triple the PFAS levels in their blood compared to the general population. Military service members at affected installations show similar elevated levels. The exposure pathways include direct skin contact with foam (recent research confirmed dermal absorption can be significant), inhalation during foam deployment, and ingestion through contaminated water.

What settlements have been reached in the AFFF water contamination cases?

Water contamination settlements in MDL 2873 total over $12 billion, anchored by 3M's $10.3 billion public water supplier settlement (approved April 2024) and DuPont/Chemours/Corteva's $1.185 billion fund (approved June 2023). These settlements fund water system testing and PFAS removal but do not resolve personal injury claims, which proceed separately on the MDL's personal injury track.

The water contamination side of the litigation has produced substantial settlements that have established the litigation framework:

Ongoing municipal litigation. Numerous individual municipalities continue to pursue PFAS claims separately from the global settlements. Kansas City, for example, announced its participation in 2024 with claims focused on Kansas City Aviation Department locations.

The water contamination settlements don't resolve personal injury claims. The settlements fund water system testing and PFAS removal but don't compensate individuals who developed cancer or other diseases from PFAS exposure. Personal injury claims continue separately on the MDL personal injury track.

How does the AFFF personal injury bellwether trial framework work?

The bellwether framework in MDL 2873 selects a small pool of representative personal injury cases for trial, focusing on cancers with the strongest scientific support (kidney, testicular, thyroid) and ulcerative colitis. The first bellwether trial, scheduled for October 2025, was vacated. Science Day proceedings continue to address Daubert and causation issues before trial dates are reset.

For personal injury cases, the bellwether trial framework focuses on specific cancers and exposure scenarios. Key features:

Bellwether plaintiff pool. Limited to 25 plaintiffs initially, with cases focused on kidney cancer, testicular cancer, thyroid disease, and ulcerative colitis. The Court selected these as having the strongest scientific support for general causation.

Two contamination site focus. Air Force bases in Colorado were identified as the primary contamination sites for the initial bellwether pool. This focus ties the bellwether cases to specific documented contamination patterns rather than diffuse general PFAS exposure.

Tier system. Cases are organized into tiers based on exposure documentation and medical evidence quality. Tier 1 cases have the strongest documentation; subsequent tiers have varying levels of supporting evidence.

First trial scheduling and delays. The first bellwether trial was scheduled for October 6, 2025 focused on kidney cancer. The trial was vacated by Case Management Order No. 35 on August 15, 2025. The Court continues to vet the influx of filings and align expert/Daubert schedules before resetting personal-injury trial dates.

Science Day proceedings. The Court has held Science Day sessions to educate the court on scientific evidence linking AFFF exposure to specific diseases. Science Day on June 20, 2025 focused on thyroid and liver cancer causation. Additional Science Day proceedings are expected as the bellwether schedule develops.

The bellwether outcomes will substantially affect global settlement discussions. If plaintiffs succeed in the bellwether trials, settlement pressure increases significantly.

Who qualifies to file an AFFF firefighting foam lawsuit?

To qualify for an AFFF personal injury claim, a plaintiff must show documented exposure to AFFF (through firefighting, military service, airport work, industrial work, or living near a contaminated site), a diagnosis of a qualifying PFAS-linked condition such as kidney or testicular cancer, a medical opinion linking the condition to PFAS, and timely filing within the applicable statute of limitations.

The eligibility framework for personal injury claims:

Documented AFFF exposure. The claimant had documented exposure to AFFF firefighting foam through:

• Firefighting work (municipal, military, industrial, or training)
• Military service at installations using AFFF
• Airport rescue and firefighting work
• Industrial work involving AFFF
• Living in communities with documented PFAS contamination from AFFF sites

Diagnosis of qualifying disease. The claimant developed one of the conditions with established or strong-developing scientific causation:

• Kidney cancer (renal cell carcinoma)
• Testicular cancer
• Thyroid cancer
• Thyroid disease (with growing evidence)
• Liver cancer
• Ulcerative colitis
• Pancreatic cancer (some firms accept)
• Prostate cancer (some firms accept based on exposure history)
• Other PFAS-linked conditions

Temporal proximity and exposure duration. The disease developed after sufficient exposure duration to support causation. PFAS cancers typically develop after years to decades of exposure, so claimants with brief exposure followed by quick cancer diagnosis have weaker causation cases.

Medical "nexus" opinion. A medical opinion linking the specific condition to PFAS exposure. The opinion needs to be from a qualified medical professional with relevant expertise.

Evidence preservation. Personnel records, training logs, duty rosters, base or municipal testing results, medical records, and similar contemporaneous documentation. Earlier evidence preservation is easier than reconstructing the exposure history years later.

Statute of limitations compliance. State-specific limitations periods apply, typically 2-3 years from diagnosis or 1-4 years from when the connection between condition and exposure was known or should have been known. The discovery rule provides some flexibility but has limits.

Specific occupational groups with strong typical eligibility:

Firefighters who worked with AFFF in training or fire response. Documentation through fire department records, training certificates, and similar evidence.

Military service members who worked with AFFF at military installations. Documentation through DD-214 service records, base assignment history, and similar evidence.

Airport rescue and firefighting personnel at airports using AFFF. Documentation through airport employment records.

Industrial workers at facilities using AFFF including oil refineries, chemical plants, and similar facilities.

Civilians who lived in communities with documented PFAS contamination from AFFF sources and used contaminated water supplies.

What are the projected AFFF lawsuit settlement amounts?

Kidney and testicular cancer cases with well-documented occupational exposure project toward $500,000 to $1 million or more. Actual values will calibrate to bellwether trial verdicts.

While no global personal injury settlement has been reached, the framework is developing:

The actual settlement amounts will depend substantially on bellwether trial outcomes.

How does the AFFF litigation compare to other mass torts?

The AFFF litigation shares a science-dependent trajectory with cases like Roundup (where strong science led to large verdicts) and serves as a contrast to the Zantac MDL (where Daubert exclusions ended federal claims). With over $10 billion in water settlements already resolved and personal injury bellwether trials pending, AFFF ranks among the highest-value active mass torts in the United States.

The AFFF litigation has unusual features compared to other active mass torts:

The broader procedural framework for mass tort settlements is detailed in our overview of how mass tort litigation works. AFFF represents one of the highest-value mass torts currently in development.

What are the strategic considerations for AFFF lawsuit plaintiffs?

Potential plaintiffs should file promptly to avoid statute of limitations issues and ensure inclusion in bellwether and settlement frameworks. Key steps include engaging AFFF-experienced counsel (most work on contingency at 30-40%), preserving exposure documentation such as personnel records and training logs, obtaining a qualified medical causation opinion, and preparing for a litigation timeline of 2-4 years or longer.

For potential plaintiffs:

Don't delay filing. The MDL has growing case volume and the Court has expressed concern about unfiled claims that may complicate global settlement discussions. Tens of thousands of viable AFFF-related injury claims remain unfiled according to plaintiffs' leadership. Filing now ensures inclusion in bellwether and settlement frameworks; waiting risks exclusion from future programs.

Engage AFFF-experienced counsel. Not all mass tort firms have substantial AFFF experience. Firms with established AFFF case books typically handle these cases more effectively than general personal injury firms. Most AFFF firms offer free consultations and work on contingency basis (typically 30-40% of recovery).

Document exposure thoroughly. Personnel records, training logs, duty rosters, base assignment history, photographs of foam use, witness statements from coworkers, medical records, and similar evidence. The case strength depends substantially on documentation quality.

Obtain qualified medical opinion. Cases require medical opinion linking the specific condition to PFAS exposure. Standard treating physicians often aren't equipped to provide the specific causation opinion needed. Specialized causation experts may be needed.

Be realistic about timeline. Personal injury bellwether trials have been delayed and the framework continues to develop. Even strong cases will likely take 2-4 years to resolve. Plaintiffs need to be prepared for extended litigation timelines.

Understand the wrongful death framework. Surviving family members of deceased AFFF plaintiffs can pursue wrongful death claims. The procedural framework is somewhat different from personal injury cases.

Statute of limitations is critical. Time-barred claims won't be revived regardless of merit. The discovery rule provides some flexibility but cases involving very old diagnoses may face limitations issues. Early consultation with counsel preserves claims that might otherwise be lost.

Consider whether to file in federal MDL or state court. Some cases may have state court options as alternatives or supplements to MDL filing. The strategic analysis depends on specific case factors.

For the broader public health context, the AFFF litigation has substantial implications beyond the individual cases. The water contamination settlements have produced significant funding for PFAS remediation. Federal regulatory action including EPA designation of PFOA and PFOS as CERCLA hazardous substances flows from the same scientific evidence that supports the litigation. The Department of Defense transition away from AFFF reflects acknowledgment of the long-term harm.

For potential plaintiffs with documented exposure and qualifying diagnoses, the framework provides meaningful paths to compensation. The work is in documenting the exposure history, obtaining qualified medical opinion linking the condition to PFAS exposure, filing within applicable limitations periods, and engaging experienced counsel who can navigate the MDL procedural framework. The bellwether trial outcomes will determine the broader settlement framework that emerges, with substantial implications for the value of individual cases. For most plaintiffs, the procedural path through MDL 2873 provides the most efficient route to recovery, with the recognition that the framework continues to develop and that the timeline for resolution depends on factors outside any individual plaintiff's control.

This post is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for guidance on your specific situation.